Kainate Receptor Antagonists:アンタゴニストのグローバル市場2015(薬開発、治験動向)

◆英語タイトル:Kainate Receptor Antagonists -Pipeline Insights, 2015
◆商品コード:DIMRMOA5416
◆発行会社(調査会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

DelveInsight’s,“Kainate Receptor Antagonists-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Kainate Receptor Antagonists. This report provides information on the therapeutic development based on the Kainate Receptor Antagonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of Kainate Receptor Antagonists
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Kainate Receptor Antagonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Kainate Receptor Antagonists and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

【レポートの目次】

• Kainate Receptor Antagonists Overview
• Kainate Receptor Antagonists Disease Associated
• Kainate Receptor Antagonists Pipeline Therapeutics
• Kainate Receptor Antagonists Therapeutics under Development by Companies
• Kainate Receptor Antagonists Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Kainate Receptor Antagonists Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Kainate Receptor Antagonists Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Kainate Receptor Antagonists Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Kainate Receptor Antagonists – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Kainate Receptor Antagonists – Discontinued Products
• Kainate Receptor Antagonists – Dormant Products
• Companies Involved in Therapeutics Development for Kainate Receptor Antagonists
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for Kainate Receptor Antagonists by Therapy Area, 2015
• Number of Products under Development for Kainate Receptor Antagonists, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Kainate Receptor Antagonists Assessment by Monotherapy Products
• Kainate Receptor Antagonists Assessment by Combination Products
• Kainate Receptor Antagonists Assessment by Route of Administration
• Kainate Receptor Antagonists Assessment by Stage and Route of Administration
• Kainate Receptor Antagonists Assessment by Molecule Type
• Kainate Receptor Antagonists Assessment by Stage and Molecule Type
• Kainate Receptor Antagonists Therapeutics – Discontinued Products
• Kainate Receptor Antagonists Therapeutics – Dormant Products
• Products under Development by Companies, 2015

• Number of Products under Development for Kainate Receptor Antagonists by Therapy Area, 2015
• Number of Products under Development for Kainate Receptor Antagonists, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Kainate Receptor Antagonists Assessment by Monotherapy Products
• Kainate Receptor Antagonists Assessment by Combination Products
• Kainate Receptor Antagonists Assessment by Route of Administration
• Kainate Receptor Antagonists Assessment by Stage and Route of Administration
• Kainate Receptor Antagonists Assessment by Molecule Type
• Kainate Receptor Antagonists Assessment by Stage and Molecule Type

【レポートのキーワード】

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

★調査レポート[Kainate Receptor Antagonists:アンタゴニストのグローバル市場2015(薬開発、治験動向)] (コード:DIMRMOA5416)販売に関する免責事項を必ずご確認ください。
★調査レポート[Kainate Receptor Antagonists:アンタゴニストのグローバル市場2015(薬開発、治験動向)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆